Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Associated Therapies
-
Clinical Trials
Related News

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

First Posted Date
2022-07-27
Last Posted Date
2024-12-06
Lead Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Target Recruit Count
54
Registration Number
NCT05476770
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Hospital Orange County, Orange, California, United States

🇺🇸

UCSF School of Medicine, San Francisco, California, United States

and more 28 locations

A Study of Olverembatinib in the Treatment of Ph+ ALL

First Posted Date
2022-07-20
Last Posted Date
2022-09-01
Lead Sponsor
Chen Suning
Target Recruit Count
55
Registration Number
NCT05466175
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

First Posted Date
2022-07-13
Last Posted Date
2024-11-20
Lead Sponsor
University of Washington
Target Recruit Count
35
Registration Number
NCT05455697
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

First Posted Date
2022-07-12
Last Posted Date
2024-04-23
Lead Sponsor
University of Washington
Target Recruit Count
30
Registration Number
NCT05453500
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

First Posted Date
2022-06-16
Last Posted Date
2024-06-17
Lead Sponsor
Li Zhiming
Target Recruit Count
50
Registration Number
NCT05422066
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

🇨🇳

Hubei Cancer Hospital, Wuhan, Hubei, China

and more 3 locations

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

First Posted Date
2022-05-25
Last Posted Date
2024-11-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT05389423
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

First Posted Date
2022-05-20
Last Posted Date
2023-10-16
Lead Sponsor
Centre Oscar Lambret
Target Recruit Count
28
Registration Number
NCT05384821
Locations
🇫🇷

CHU de MONTPELLIER - Hôpital Arnaud de Villeneuve, Montpellier, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

CHRU NANCY - Hôpital d'Enfants, Vandœuvre-lès-Nancy, France

and more 13 locations

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

First Posted Date
2022-05-19
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
225
Registration Number
NCT05382338
Locations
🇺🇸

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

🇺🇸

Kaiser Permanente-Oakland, Oakland, California, United States

🇺🇸

State University of New York Upstate Medical University, Syracuse, New York, United States

and more 58 locations

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

First Posted Date
2022-05-12
Last Posted Date
2024-11-22
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
230
Registration Number
NCT05371093
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States

🇺🇸

UC Irvine Health, Orange, California, United States

and more 65 locations

Vincristine Pharmacokinetics in Infants

First Posted Date
2022-05-03
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
83
Registration Number
NCT05359237
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

and more 26 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy